Modern Healthcare June 9, 2017
Shelby Livingston

Paying for certain high-cost drugs based on the patient outcomes they deliver is becoming increasingly necessary in the face of skyrocketing drug costs in the U.S., the CEOs of a health insurance company and a pharmaceutical giant agreed Thursday.

The two industries rarely see eye to eye. Harvard Pilgrim Health Care CEO Eric Schultz and Eli Lilly CEO David Ricks joked Thursday at the 2017 AHIP Institute and Expo in Austin, Texas, that they almost called off their panel discussion for fear of having to sit next to each other. But the two found common ground on value-based agreements.

“We in the health insurance industry have used payment for value, payment for performance, for many years with physicians and hospitals,”...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: ACO (Accountable Care), CMS, Health System / Hospital, MACRA, Medicaid, Medicare, Medicare Advantage, Patient / Consumer, Payer, Physician, Primary care, Private Exchange, Provider, Public Exchange, Self-insured, Value Based
Related Articles:
Why Highmark trained thousands of leaders on AI prompt engineering
Why an MD alone is ‘practically worthless’ for physician leaders today
Is there a doctor fix in the House?
Europeans Have Lost Millions of Years of Life to COVID
Food Is Medicine In The US: A National Survey Of Public Perceptions Of Care, Practices, And Policies

Share This Article